Review article
Drugs for migraine prophylaxis
Dtsch Arztebl Int 2026; 123: 119-26. DOI: 10.3238/arztebl.m2025.0234
; ;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
Abteilung für Neuroepidemiologie, Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), Medizinische Fakultät der Universität Duisburg-Essen, Essen: Prof. Dr. med. Hans Christoph Diener, Dr. rer. nat. Julia Grans
Klinik für Neurologie, Charité Universitätsmedizin Berlin, und Universitätsklinikum Bonn: Prof. Dr. med. Uwe Reuter
Klinik für Neurologie, Charité Universitätsmedizin Berlin, und Universitätsklinikum Bonn: Prof. Dr. med. Uwe Reuter
| 1. | Porst M, Wengler A, Leddin J, et al.: Migraine and tension-type headache in Germany. Prevalence and disease severity from the BURDEN 2020 Burden of Disease Study. J Health Monit 2020; 5: 2–24 CrossRef MEDLINE PubMed Central |
| 2. | Diener HC, Förderreuther S, Kropp P, Reuter U, et al.: Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie. DGN und DMKG, in: Deutsche Gesellschaft für Neurologie (eds.), Leitlinien für Diagnostik und Therapie in der Neurologie 2025. www.dgn.org/leitlinien (last accessed on 19 January 2026). CrossRef |
| 3. | Headache Classification Committee of the International Headache Society (IHS): The international classification of headache disorders ICHD-3, 3rd edition. Cephalalgia 2018; 38: 1–211. CrossRef |
| 4. | Ashina S, Terwindt GM, Steiner TJ, et al.: Medication overuse headache. Nat Rev Dis Primers 2023; 9: 5. CrossRef MEDLINE |
| 5. | Ornello R, Caponnetto V, Ahmed F, et al.: Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia 2025; 45: 3331024251321500. CrossRef |
| 6. | Ornello R, Caponnetto V, Ahmed F, et al.: Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia 2025; 45: 3331024241305381. CrossRef MEDLINE |
| 7. | Puledda F, Sacco S, Diener HC, et al.: International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia 2024; 44: 3331024241269735. CrossRef MEDLINE |
| 8. | Holroyd KA, Penzien DB, Cordingley GE: Propranolol in the management of recurrent migraine: A meta-analytic review. Headache 1991; 31: 333–40. CrossRef MEDLINE |
| 9. | Silberstein SP, Goadsby PB: Migraine: Preventive treatment. Cephalalgia 2002; 22: 491–512. CrossRef MEDLINE |
| 10. | Jackson JL, Kuriyama A, Kuwatsuka Y, et al.: Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14: e0212785. CrossRef MEDLINE PubMed Central |
| 11. | Jackson JL, Cogbill E, Santana-Davila R, et al.: A comparative effectiveness meta-Analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10: e0130733. CrossRef MEDLINE PubMed Central |
| 12. | Kangasniemi P, Andersen AR, Andersson PG, et al.: Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 7: 231–8. CrossRef MEDLINE |
| 13. | Steiner TJ, Joseph R, Hedman C, Clifford Rose F: Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache 1988; 28: 15–23. CrossRef MEDLINE |
| 14. | Linde K, Rossnagel K: Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004: CD003225. CrossRef |
| 15. | Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M: Flunarizine as prophylaxis for episodic migraine: A systematic review with meta-analysis. Pain 2019; 160: 762–72. CrossRef MEDLINE |
| 16. | Deligianni CI, Sacco S, Ekizoglu E, et al.: European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: Flunarizine. J Headache Pain 2023; 24: 128. CrossRef MEDLINE PubMed Central |
| 17. | Lampl C, Versijpt J, Amin FM, et al.: European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: Amitriptyline. J Headache Pain 2023; 24: 39. CrossRef MEDLINE PubMed Central |
| 18. | Couch JR: Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011; 51: 33–51. CrossRef MEDLINE |
| 19. | Brandes J, Saper J, Diamond M, et al.: Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004; 291: 965–73. CrossRef MEDLINE |
| 20. | Diener HC, Tfelt-Hansen P, Dahlöf C, et al.: Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943–50. CrossRef MEDLINE |
| 21. | Silberstein SD, Lipton RB, Dodick DW, et al.: Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170–80. CrossRef MEDLINE |
| 22. | Lainez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S: Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007; 14: 900–6. CrossRef MEDLINE |
| 23. | Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ: Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814–23. CrossRef MEDLINE |
| 24. | Silberstein SD: Topiramate in migraine prevention: A 2016 perspective. Headache 2017; 57: 165–78. CrossRef MEDLINE |
| 25. | Aurora SK, Dodick DW, Turkel CC, et al.: OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793–803. CrossRef MEDLINE |
| 26. | Diener HC, Dodick DW, Aurora SK, et al.: OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804–14. CrossRef MEDLINE |
| 27. | Dodick DW, Turkel CC, DeGryse RE, et al.: OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921–36. CrossRef MEDLINE |
| 28. | Bruijn NRA, Huessler EM, MaassenVanDenBrink A, et al.: Placebo response in acute and prophylactic treatment of migraine: A systematic review and meta-analysis covering 36 years of research. Neurol Clin 2025; 44: 23–45. CrossRef MEDLINE |
| 29. | Silberstein SD, Blumenfeld AM, Cady RK, et al.: OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331: 48–56. CrossRef MEDLINE |
| 30. | Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A: Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018; 19: 13. CrossRef MEDLINE PubMed Central |
| 31. | Wong HT, Khan R, Buture A, Khalil M, Ahmed F: OnabotulinumtoxinA treatment for chronic migraine in pregnancy: an updated report of real-world headache and pregnancy outcomes over 14 years in Hull. Cephalalgia 2025; 45: 3331024251327387. CrossRef MEDLINE |
| 32. | Deng H, Li GG, Nie H, et al.: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine—an updated systematic review and meta-analysis. BMC Neurol 2020; 20: 57. CrossRef MEDLINE PubMed Central |
| 33. | Soni P, Chawla E: Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. Clin Neurol Neurosurg 2021; 209: 106893. CrossRef MEDLINE |
| 34. | Reuter U, Ehrlich M, Gendolla A, et al.: Erenumab versus topiramate for the prevention of migraine—a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 2022; 42: 108–118. CrossRef MEDLINE PubMed Central |
| 35. | Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P: Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 2023; 43: 03331024231159366. CrossRef MEDLINE |
| 36. | Mistry H, Naghdi S, Brown A, et al.: Preventive drug treatments for adults with chronic migraine: A systematic review with economic modelling. Health Technol Assess 2024; 28: 1–329. CrossRef |
| 37. | Tepper SJ, Lipton RB, Silberstein SD, et al.: Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache 2023; 63: 730–42. CrossRef MEDLINE |
| 38. | Frank F, Ulmer H, Sidoroff V, Broessner G: CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia 2021; 41: 1222–39. CrossRef MEDLINE PubMed Central |
| 39. | Diener HC, Rizzoli P: Chronic migraine and medication overuse. Handb Clin Neurol 2023; 198: 187–200. CrossRef MEDLINE |
| 40. | Alpuente A, Torres-Ferrus M, Terwindt GM: Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache. Cephalalgia 2023; 43: 03331024221150235. CrossRef |
| e1. | Tepper SJ, Dodick DW, Lanteri-Minet M, et al.: Efficacy and safety of erenumab for nonopioid medication overuse headache in chronic migraine: A phase 4, randomized, placebo-controlled trial. JAMA Neurology 2024; 81: 1140–9. CrossRef MEDLINE PubMed Central |
| e2. | Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM: Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol 2022; 12: 788159. CrossRef MEDLINE PubMed Central |
| e3. | Wang X, Chen Y, Song J, You C: Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: A systematic review and network meta-analysis. Front Pharmacol 2021; 12: 649143. CrossRef MEDLINE PubMed Central |
| e4. | Wang Q, Liu J, Sun H, et al.: Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database. Expert Opin Drug Saf 2024; 23: 107–17. CrossRef MEDLINE |
| e5. | Ailani J, Burch RC, Robbins MS, the board of directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61: 1021–39. CrossRef MEDLINE |
| e6. | Overeem LH, Peikert A, Hofacker MD, et al.: Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 2022; 42: 291–301. CrossRef MEDLINE PubMed Central |
| e7. | McAllister P, Winner PK, Ailani J, et al.: Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: Secondary results from the randomized controlled RELIEF study. J Headache Pain 2022; 23: 22. CrossRef MEDLINE PubMed Central |
| e8. | Ashina M, Goadsby PJ, Reuter U, et al.: Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 2021; 28: 1716–25. CrossRef MEDLINE PubMed Central |
| e9. | Raffaelli B, De Icco R, Corrado M, Terhart M, Ailani J: Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review. Cephalalgia 2023; 43: 03331024221137091. CrossRef MEDLINE |
| e10. | Moore E, Bell IM, Fraley ME, et al.: Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist. Cephalalgia 2024; 44: 3331024231226186. CrossRef MEDLINE |
| e11. | Boinpally R, Shebley M, Trugman JM: Atogepant: mechanism of action, clinical and translational science. Clin Transl Sci 2024; 17: e13707. CrossRef MEDLINE PubMed Central |
| e12. | Ailani J, Lipton RB, Goadsby PJ, et al.: Atogepant for the preventive treatment of migraine. N Engl J Med 2021; 385: 695–706. CrossRef MEDLINE |
| e13. | Pozo-Rosich P, Ailani J, Ashina M, et al.: Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402: 775–85. CrossRef MEDLINE PubMed Central |
| e14. | Goadsby PJ, Friedman DI, Holle-Lee D, et al.: Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology 2024; 103: e209584. CrossRef MEDLINE PubMed Central |
| e15. | Croop R, Lipton RB, Kudrow D, et al.: Oral rimegepant for preventive treatment of migraine: A phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021: 397: 51–60. CrossRef MEDLINE |
| e16. | Schwedt TJ, Myers Oakes TM, Martinez JM, et al.: Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther 2024; 13: 85–105. CrossRef MEDLINE PubMed Central |
| e17. | Goadsby PJ, Dodick DW, Ailani J, et al.: Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol 2020; 19: 727–37. CrossRef MEDLINE |
| e18. | Tassorelli C, Nagy K, Pozo-Rosich P, et al.: Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): A randomised, placebo-controlled, phase 3b trial. Lancet Neurol 2024; 23: 382–92. CrossRef MEDLINE |
| e19. | Ashina M, Saper J, Cady R, et al.: Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40: 241–54. CrossRef MEDLINE PubMed Central |
| e20. | Sun H, Dodick DW, Silberstein S, et al.: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 382–90. CrossRef MEDLINE |
| e21. | Goadsby PJ, Reuter U, Hallström Y, et al.: A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377: 2123–32. CrossRef MEDLINE |
| e22. | Dodick DW, Ashina M, Brandes JL, et al.: ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38: 1026–37. CrossRef MEDLINE PubMed Central |
| e23. | Sakai F, Takeshima T, Tatsuoka Y, et al.: A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 2019; 59: 1731–42. CrossRef MEDLINE PubMed Central |
| e24. | Wang SJ, Roxas AA, Jr., Saravia B, et al.: Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia 2021; 41: 1285–97. CrossRef MEDLINE PubMed Central |
| e25. | Takeshima T, Sakai F, Hirata K, et al.: Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache 2021; 61: 927–35. CrossRef MEDLINE PubMed Central |
| e26. | Reuter U, Goadsby PJ, Lanteri-Minet M, et al.: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392: 2280–7. CrossRef MEDLINE |
| e27. | Bigal ME, Dodick DW, Rapoport AM, et al.: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14: 1081–90. CrossRef MEDLINE |
| e28. | Dodick DW, Silberstein SD, Bigal ME, et al.: Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA 2018; 319: 1999–2008. CrossRef MEDLINE PubMed Central |
| e29. | Sakai F, Suzuki N, Kim BK, et al.: Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 2021; 61: 1102–11. CrossRef MEDLINE PubMed Central |
| e30. | Ferrari MD, Diener HC, Ning X, et al.: Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394: 1030–40. CrossRef MEDLINE |
| e31. | Skljarevski V, Oakes TM, Zhang Q, et al.: Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: A randomized clinical trial. JAMA Neurol 2018; 75: 187–93. CrossRef MEDLINE PubMed Central |
| e32. | Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75: 1080–8. CrossRef MEDLINE PubMed Central |
| e33. | Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY: Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38: 1442–54. CrossRef MEDLINE |
| e34. | Sakai F, Ozeki A, Skljarevski V: Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Reports 2020; 3. CrossRef |
| e35. | Mulleners WM, Kim BK, Láinez MJA, et al.: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19: 814–25. CrossRef MEDLINE |
| e36. | Hu B, Li G, Li X, et al.: Galcanezumab in episodic migraine: The phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain 2022; 23: 90. CrossRef MEDLINE PubMed Central |
| e37. | MaassenVanDenBrink A, Terwindt GM, Cohen JM, et al.: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: Results of the randomized, placebo-controlled, phase 3b FOCUS study. J Headache Pain 2021; 22: 152. CrossRef MEDLINE PubMed Central |
| e38. | Dodick DW, Lipton RB, Silberstein S, et al.: Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 2019; 39: 1075–85. CrossRef MEDLINE |
| e39. | Lipton RB, Goadsby PJ, Smith J, et al.: Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94: e1365–e77. CrossRef |
| e40. | Tepper S, Ashina M, Reuter U, et al.: Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 425–34. CrossRef MEDLINE PubMed Central |
| e41. | Yu S, Kim BK, Wang H, et al.: A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 2022; 23: 146. CrossRef MEDLINE PubMed Central |
| e42. | Bigal ME, Edvinsson L, Rapoport AM, et al.: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14: 1091–100. CrossRef |
| e43. | Silberstein SD, Dodick DW, Bigal ME, et al.: Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377: 2113–22. CrossRef MEDLINE PubMed Central |
| e44. | Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK: Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91: e2211–e21. CrossRef MEDLINE PubMed Central |
| e45. | Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al.: Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022; 21: 597–607. CrossRef MEDLINE |
| e46. | Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, et al.: Fremanezumab for the treatment of patients with migraine and comorbid major depressive disorder: The UNITE randomized clinical trial. JAMA Neurol 2025; 82: 560–9. CrossRef MEDLINE PubMed Central |
| e47. | Lampl C, MaassenVanDenBrink A, Deligianni CI, et al.: The comparative effectiveness of migraine preventive drugs: A systematic review and network meta-analysis. J Headache Pain 2023; 24: 56. CrossRef MEDLINE PubMed Central |
| e48. | Raffaelli B, Terhart M, Overeem LH, et al.: Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: A prospective, longitudinal cohort study. Cephalalgia 2022; 42: 326–34. CrossRef MEDLINE PubMed Central |
| e49. | Terhart M, Mecklenburg J, Neeb L, et al.: Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain 2021; 22: 158. CrossRef MEDLINE PubMed Central |